Literature DB >> 23606072

Top 10 things to know about lupus activity measures.

Aikaterini Thanou1, Joan T Merrill.   

Abstract

Accurately measuring lupus disease activity has been a demanding and still unresolved task, considering the complex multisystem nature of the disease and its variability over time and between patients. Various available tools for measurement of lupus disease activity may detect clinical improvement and/or deterioration and can be global or organ-focused. Several measures have demonstrated validity, reliability, and sensitivity to change in observational studies, and some were found useful in randomized controlled trials. Evaluation of their content and metric properties and critical review of their strengths and weaknesses facilitates selection of the appropriate tool according to the outcome of interest, and forms the basis for their optimization. In this review, we highlight recent progress in lupus disease activity measures and point to future directions in this field, with a focus on novel composite measurements derived by combining outcome measures in ways that might compensate for their individual deficiencies.

Entities:  

Mesh:

Year:  2013        PMID: 23606072     DOI: 10.1007/s11926-013-0334-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  41 in total

1.  International consensus for a definition of disease flare in lupus.

Authors:  N Ruperto; L M Hanrahan; G S Alarcón; H M Belmont; R L Brey; P Brunetta; J P Buyon; M I Costner; M E Cronin; M A Dooley; G Filocamo; D Fiorentino; P R Fortin; A G Franks; G Gilkeson; E Ginzler; C Gordon; J Grossman; B Hahn; D A Isenberg; K C Kalunian; M Petri; L Sammaritano; J Sánchez-Guerrero; R D Sontheimer; V Strand; M Urowitz; J M von Feldt; V P Werth; J T Merrill
Journal:  Lupus       Date:  2010-12-10       Impact factor: 2.911

2.  BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.

Authors:  D A Isenberg; A Rahman; E Allen; V Farewell; M Akil; I N Bruce; D D'Cruz; B Griffiths; M Khamashta; P Maddison; N McHugh; M Snaith; L S Teh; C S Yee; A Zoma; C Gordon
Journal:  Rheumatology (Oxford)       Date:  2005-04-06       Impact factor: 7.580

3.  Accurately describing changes in disease activity in Systemic Lupus Erythematosus.

Authors:  D D Gladman; M B Urowitz; A Kagal; D Hallett
Journal:  J Rheumatol       Date:  2000-02       Impact factor: 4.666

4.  SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation.

Authors:  Z Touma; M B Urowitz; D Ibañez; D D Gladman
Journal:  Lupus       Date:  2011-01       Impact factor: 2.911

5.  Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity.

Authors:  Chee-Seng Yee; Vernon Farewell; David A Isenberg; Athiveeraramapandian Prabu; Katharina Sokoll; Lee-Suan Teh; Anisur Rahman; Ian N Bruce; Bridget Griffiths; Mohammed Akil; Neil McHugh; David D'Cruz; Munther A Khamashta; Simon Bowman; Peter Maddison; Asad Zoma; Elizabeth Allen; Caroline Gordon
Journal:  Arthritis Rheum       Date:  2006-10

6.  Numerical scoring for the BILAG-2004 index.

Authors:  Chee-Seng Yee; Lynne Cresswell; Vernon Farewell; Anisur Rahman; Lee-Suan Teh; Bridget Griffiths; Ian N Bruce; Yasmeen Ahmad; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; David D'Cruz; Munther A Khamashta; David A Isenberg; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2010-02-24       Impact factor: 7.580

Review 7.  Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI).

Authors:  Juanita Romero-Diaz; David Isenberg; Rosalind Ramsey-Goldman
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

8.  The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients.

Authors:  Chee-Seng Yee; Vernon T Farewell; David A Isenberg; Bridget Griffiths; Lee-Suan Teh; Ian N Bruce; Yasmeen Ahmad; Anisur Rahman; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; Christopher Edwards; David D'Cruz; Munther A Khamashta; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2011-01-18       Impact factor: 7.580

9.  British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.

Authors:  Chee-Seng Yee; Vernon Farewell; David A Isenberg; Anisur Rahman; Lee-Suan Teh; Bridget Griffiths; Ian N Bruce; Yasmeen Ahmad; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; David D'Cruz; Munther A Khamashta; Peter Maddison; Caroline Gordon
Journal:  Arthritis Rheum       Date:  2007-12

10.  The BILAG-2004 index is sensitive to change for assessment of SLE disease activity.

Authors:  Chee-Seng Yee; Vernon Farewell; David A Isenberg; Bridget Griffiths; Lee-Suan Teh; Ian N Bruce; Yasmeen Ahmad; Anisur Rahman; Athiveeraramapandian Prabu; Mohammed Akil; Neil McHugh; Christopher Edwards; David D'Cruz; Munther A Khamashta; Peter Maddison; Caroline Gordon
Journal:  Rheumatology (Oxford)       Date:  2009-04-24       Impact factor: 7.580

View more
  6 in total

Review 1.  New Trials in Lupus and where Are we Going.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2018-05-03       Impact factor: 4.592

Review 2.  Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Nat Rev Rheumatol       Date:  2013-10-08       Impact factor: 20.543

Review 3.  Clinical disease activity and flare in SLE: Current concepts and novel biomarkers.

Authors:  Aikaterini Thanou; Eldon Jupe; Mohan Purushothaman; Timothy B Niewold; Melissa E Munroe
Journal:  J Autoimmun       Date:  2021-02-22       Impact factor: 7.094

4.  Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments.

Authors:  Anca Askanase; Xiaoqing Li; Avery Pong; Katrina Shum; Stan Kamp; Fredonna Carthen; Teresa Aberle; Leslie Hanrahan; Paola Daly; Jon Giles; Joan T Merrill
Journal:  Lupus Sci Med       Date:  2015-03-04

5.  Impact of heart rate variability, a marker for cardiac health, on lupus disease activity.

Authors:  Aikaterini Thanou; Stavros Stavrakis; John W Dyer; Melissa E Munroe; Judith A James; Joan T Merrill
Journal:  Arthritis Res Ther       Date:  2016-09-02       Impact factor: 5.156

6.  Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures.

Authors:  Aikaterini Thanou; Judith A James; Cristina Arriens; Teresa Aberle; Eliza Chakravarty; Joseph Rawdon; Stavros Stavrakis; Joan T Merrill; Anca Askanase
Journal:  Lupus Sci Med       Date:  2019-12-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.